
FASENRA in MANDARA Phase III: Remission Achievable in EGPA, NEJM Publishes Results
The MANDARA Phase III trial published in the New England Journal of Medicine and presented at the AAAAI Annual Meeting reveals promising outcomes for FASENRA® (benralizumab) in treating EGPA. This marks the first head-to-head comparison of biologics for EGPA and…












